See more : Ascom Holding AG (ASCN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of CinCor Pharma, Inc. (CINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CinCor Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Korn Ferry (KFY) Income Statement Analysis – Financial Results
- PBF Logistics LP (PBFX) Income Statement Analysis – Financial Results
- Shanghai Fudan Forward S&T Co., Ltd (600624.SS) Income Statement Analysis – Financial Results
- Osotspa Public Company Limited (OSOPF) Income Statement Analysis – Financial Results
- SPARINVEST BÆREDYGTIGE AKTIER AKK (SPIBDAAKKKLA.CO) Income Statement Analysis – Financial Results
CinCor Pharma, Inc. (CINC)
About CinCor Pharma, Inc.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.51M | 17.95M | 3.93M |
| General & Administrative | 21.00M | 3.17M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 21.00M | 3.17M | 1.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.51M | 21.13M | 5.14M |
| Cost & Expenses | 42.51M | 21.13M | 5.14M |
| Interest Income | 21.64K | 36.73K | 101.71K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.88M | 1.21M | 171.86K |
| EBITDA | -34.63M | -19.92M | -5.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.51M | -21.13M | -5.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.86M | -1.17M | 101.71K |
| Income Before Tax | -50.37M | -22.30M | -5.04M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -21.64K | -36.73K | -101.71K |
| Net Income | -50.35M | -22.26M | -4.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.42 | -0.95 | -0.21 |
| EPS Diluted | -1.42 | -0.95 | -0.21 |
| Weighted Avg Shares Out | 35.42M | 23.49M | 23.49M |
| Weighted Avg Shares Out (Dil) | 35.42M | 23.49M | 23.49M |
There's a Lot to Love About Mineralys' Valentine's Day IPO
It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volume, there certainly appears to be...
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.
NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed...
Why Is CinCor (CINC) Stock Up 138% Today?
CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.
AstraZeneca to acquire CinCor for US$1.8bn
AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued...
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
CinCor's hypertension drug misses primary endpoint in mid-stage study
Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to...
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:
Source: https://incomestatements.info
Category: Stock Reports